keyword
MENU ▼
Read by QxMD icon Read
search

high dose cytarabine renal failure

keyword
https://www.readbyqxmd.com/read/27377614/comparative-toxicities-of-3-platinum-containing-chemotherapy-regimens-in-relapsed-refractory-lymphoma-patients
#1
F Tixier, F Ranchon, A Iltis, N Vantard, V Schwiertz, E Bachy, F Bouafia-Sauvy, C Sarkozy, J F Tournamille, E Gyan, G Salles, C Rioufol
Optimal salvage chemotherapy regimen for patients with relapsed or refractory Hodgkin and non-Hodgkin lymphoma remains unclear but often based on platinum regimens. This retrospective study assesses in real life the toxicities profiles of patients with relapsed or refractory lymphoma treated with DHA (dexamethasone, high dose aracytine cytarabine) plus platinum salt (dexamethasone-High dose aracytine (cis)platin (DHAP), dexamethasone-High dose aracytine carboplatin (DHAC), or dexamethasone-High dose aracytine Oxaliplatin (DHAOX)), from February 2007 to May 2013 in 2 French hospitals...
July 5, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27313086/addition-of-high-dose-cytarabine-to-immunochemotherapy-before-autologous-stem-cell-transplantation-in-patients-aged-65-years-or-younger-with-mantle-cell-lymphoma-mcl-younger-a-randomised-open-label-phase-3-trial-of-the-european-mantle-cell-lymphoma-network
#2
RANDOMIZED CONTROLLED TRIAL
Olivier Hermine, Eva Hoster, Jan Walewski, André Bosly, Stephan Stilgenbauer, Catherine Thieblemont, Michal Szymczyk, Reda Bouabdallah, Michael Kneba, Michael Hallek, Gilles Salles, Pierre Feugier, Vincent Ribrag, Josef Birkmann, Roswitha Forstpointner, Corinne Haioun, Mathias Hänel, René Olivier Casasnovas, Jürgen Finke, Norma Peter, Kamal Bouabdallah, Catherine Sebban, Thomas Fischer, Ulrich Dührsen, Bernd Metzner, Georg Maschmeyer, Lothar Kanz, Christian Schmidt, Richard Delarue, Nicole Brousse, Wolfram Klapper, Elizabeth Macintyre, Marie-Hélène Delfau-Larue, Christiane Pott, Wolfgang Hiddemann, Michael Unterhalt, Martin Dreyling
BACKGROUND: Mantle cell lymphoma is characterised by a poor long-term prognosis. The European Mantle Cell Lymphoma Network aimed to investigate whether the introduction of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation (ASCT) improves outcome. METHODS: This randomised, open-label, parallel-group, phase 3 trial was done in 128 haemato-oncological hospital departments or private practices in Germany, France, Belgium, and Poland...
August 6, 2016: Lancet
https://www.readbyqxmd.com/read/26549589/addition-of-sorafenib-versus-placebo-to-standard-therapy-in-patients-aged-60-years-or-younger-with-newly-diagnosed-acute-myeloid-leukaemia-soraml-a-multicentre-phase-2-randomised-controlled-trial
#3
RANDOMIZED CONTROLLED TRIAL
Christoph Röllig, Hubert Serve, Andreas Hüttmann, Richard Noppeney, Carsten Müller-Tidow, Utz Krug, Claudia D Baldus, Christian H Brandts, Volker Kunzmann, Hermann Einsele, Alwin Krämer, Kerstin Schäfer-Eckart, Andreas Neubauer, Andreas Burchert, Aristoteles Giagounidis, Stefan W Krause, Andreas Mackensen, Walter Aulitzky, Regina Herbst, Mathias Hänel, Alexander Kiani, Norbert Frickhofen, Johannes Kullmer, Ulrich Kaiser, Hartmut Link, Thomas Geer, Albert Reichle, Christian Junghanß, Roland Repp, Frank Heits, Heinz Dürk, Jana Hase, Ina-Maria Klut, Thomas Illmer, Martin Bornhäuser, Markus Schaich, Stefani Parmentier, Martin Görner, Christian Thiede, Malte von Bonin, Johannes Schetelig, Michael Kramer, Wolfgang E Berdel, Gerhard Ehninger
BACKGROUND: Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the treatment of acute myeloid leukaemia. We investigated the efficacy and tolerability of sorafenib versus placebo in addition to standard chemotherapy in patients with acute myeloid leukaemia aged 60 years or younger. METHODS: This randomised, double-blind, placebo-controlled, phase 2 trial was done at 25 sites in Germany...
December 2015: Lancet Oncology
https://www.readbyqxmd.com/read/24881921/posterior-reversible-encephalopathy-syndrome-following-acute-pancreatitis-during-chemotherapy-for-acute-monocytic-leukemia
#4
Mitsutaka Nishimoto, Hideo Koh, Masato Bingo, Masahiro Yoshida, Satoru Nanno, Yoshiki Hayashi, Takahiko Nakane, Hirohisa Nakamae, Taro Shimono, Masayuki Hino
We describe an 18-year-old man with acute leukemia who presented with posterior reversible encephalopathy syndrome (PRES) shortly after developing acute pancreatitis. On day 15 after the third consolidation course with high-dose cytarabine, treatment with broad-spectrum antibiotics was initiated for febrile neutropenia. On day 16, he developed septic shock, and subsequently, acute respiratory distress syndrome (ARDS). After adding vancomycin, micafungin and high-dose methylprednisolone (mPSL) to his treatment regimen, these manifestations subsided...
May 2014: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/23420764/simultaneous-determination-of-cytosine-arabinoside-and-its-metabolite-uracil-arabinoside-in-human-plasma-using-hydrophilic-interaction-liquid-chromatography-with-uv-detection
#5
Masanobu Uchiyama, Yasushi Takamatsu, Kentaro Ogata, Taichi Matsumoto, Shiro Jimi, Kazuo Tamura, Shuuji Hara
A practical high-performance liquid chromatography using a Cosmosil HILIC column and UV detection was developed for determining the concentrations of cytosine arabinoside (Ara-C) and uracil arabinoside (Ara-U), which is a major metabolite of Ara-C, in human plasma. This method was used to determine the plasma concentrations of Ara-C and Ara-U in a patient treated with high-dose Ara-C therapy for end-stage renal failure.
July 2013: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/22858572/early-mortality-in-children-with-advanced-mature-b-cell-malignancies-in-a-middle-income-country
#6
Carolina Cervio, Dario Barsotti, Juan Ibanez, Hugo Paganini, María Sara Felice, Guillermo L Chantada
Scant information about the early toxicity of high-dose chemotherapy regimens for the treatment of mature B-cell malignancies (B-non-Hodgkin lymphoma) in developing countries is available, so we performed a retrospective evaluation of children with B-non-Hodgkin lymphoma treated with Berlin-Frankfurt-Muenster-based protocols in Argentina (1993 to 2007). In the second protocol, induction chemotherapy was modified introducing high-dose cytarabine and etoposide (block CC) instead of high-dose methotrexate (block AA)...
October 2012: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/20532508/effective-clearance-of-ara-u-the-major-metabolite-of-cytosine-arabinoside-ara-c-by-hemodialysis-in-a-patient-with-lymphoma-and-end-stage-renal-failure
#7
Dejan Radeski, Gavin M Cull, Michael Cain, L Peter Hackett, Kenneth F Ilett
PURPOSE: We report that hemodialysis clears Ara-U from the blood after high-dose Ara-C treatment in a patient with lymphoma and end-stage renal failure. METHODS: The patient received two doses of Ara-C 1 g/m(2) 24 h apart and was hemodialyzed at about 6 h after each dose and subsequently as per her usual dialysis schedule. Multiple blood samples were collected after dosing. Blood and dialyzate were also collected from the dialysis circuit during a second identical treatment cycle...
April 2011: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/20379101/-effectiveness-of-remission-induction-with-high-dose-cytarabine-for-relapsed-or-refractory-pediatric-acute-leukemia
#8
MULTICENTER STUDY
Yasuo Horikoshi, Ryoji Kobayashi, Mikiya Endo, Arata Watanabe, Atsushi Kikuta, Kazutoshi Koike, Ryoji Hanada, Ryota Hosoya, Akira Ohara, Koichiro Ikuta, Hiroaki Goto, Keiko Asami, Kanji Sugita, Keizo Horibe, Masahito Tsurusawa, Toshinari Hori, Junichi Hara, Shinichiro Nishimura, Yoshihisa Nagatoshi, Hideo Mugishima, Shigeru Ohta, Souichi Adachi, Ichiro Tsukimoto
We conducted a multicenter postmarketing study to investigate the efficacy and safety of reinduction therapy with a high-dose cytarabine-containing regimen for pediatric patients with relapsed or refractory acute leukemia. Seven of 13 patients (53.8%) with ALL achieved complete or partial remission, and only 1 of 6 patients (16.7%) with AML achieved partial remission. The frequent non-hematologic adverse events were gastrointestinal toxicities, such as vomiting, diarrhea and abdominal pain, as well as pyrexia and headache...
February 2010: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/19812012/-therapeutic-management-of-central-nervous-system-lymphomas-in-a-single-hematological-institute
#9
János László Iványi, Eva Marton, Márk Plander, Gabriella Gyánó, László Czumbil, Csaba Tóth
UNLABELLED: Primary central nervous system lymphoma is defined as an extranodal lymphoma arising in the central nervous system in the absence of systemic disease. Because of their rare occurrence among lymphomas, optimal treatment could hardly be established. AIMS: In this retrospective survey we analyzed the result of combined treatment (systemic and intrathecal chemotherapy followed by consolidation radiotherapy) in patients with primary or relapsed central nervous system lymphomas diagnosed and treated in our hematological department between 1998-2009...
October 18, 2009: Orvosi Hetilap
https://www.readbyqxmd.com/read/18836794/arau-accumulation-in-patients-with-renal-insufficiency-as-a-potential-mechanism-for-cytarabine-neurotoxicity
#10
L H Lindner, H Ostermann, W Hiddemann, A Kiani, M Würfel, T Illmer, C Karsch, U Platzbecker, G Ehninger, E Schleyer
Neurotoxicity of cytarabine (AraC) is believed to be related to renal insufficiency. We examined the plasma pharmacokinetics of AraC and its deamination product uracil arabinoside (AraU) in four patients with AML and concomitant severe renal insufficiency after treatment with AraC. Additionally, in one of these patients the concentration of intracellular AraCTP, the active metabolite of AraC, was analysed. Patients 2 and 3 were treated with AraC 1.0 g/m(2) infused for 3 h at 12-h intervals on days 1-4. Patient 1 received the same schedule of AraC with 0...
November 2008: International Journal of Hematology
https://www.readbyqxmd.com/read/17017664/eshap-salvage-therapy-for-refractory-and-relapsed-non-hodgkin-s-lymphoma-a-single-center-experience
#11
Sang Hyoung Park, Shin Kim, Ok Bae Ko, Ja Eun Koo, Danbi Lee, Yong Pil Jeong, Jooryung Huh, Sung-Bae Kim, Sang We Kim, Jae-Lyun Lee, Cheolwon Suh
BACKGROUND: The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials. We attempted to determine whether ESHAP therapy would be effective and well-tolerated in Korean patients. METHODS: Twenty two patients with refractory or relapsed NHLs (all aggressive types) were enrolled in this study...
September 2006: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/12431237/fulminant-tumour-lysis-syndrome-in-acute-myelogenous-leukaemia-with-inv-16-p13-q22
#12
M D Seftel, H Bruyere, M Copland, D E Hogge, D E Horsman, S H Nantel, J D Shepherd, J C Lavoie, A Le, H J Sutherland, C L Toze, T J Nevill
Tumour lysis syndrome (TLS) is caused by rapid breakdown of malignant cells resulting in electrolyte disturbances and acute renal failure. TLS has rarely been described in patients with acute myelogenous leukaemia (AML). Between November 1997 and July 2001, 114 consecutive adult AML patients aged <60 yr received induction chemotherapy consisting of cytosine arabinoside 1.5 g m(-2) q 12 h x 12 doses and daunorubicin 45 mg m(-2) d(-1) x 3 doses. During induction chemotherapy (CT), seven patients (6.1%, 95% CI 2...
October 2002: European Journal of Haematology
https://www.readbyqxmd.com/read/12180108/a-dose-escalation-study-for-salvage-chemotherapy-in-patients-with-refractory-lymphoma-prior-to-high-dose-myeloablative-therapy-with-stem-cell-transplantation
#13
C K Lee, M de Magalhaes-Silverman, M Hayashi, A Schlueter, R G Strauss, R J Hohl, R D Gingrich
Chemosensitive response prior to transplantation has been shown to be most significant for survival post transplant. To estimate toxicity of a dose-intensive regimen that was to improve chemosensitive response rate, 15 patients with primary refractory lymphoma were enrolled in dose escalation of pre-transplant salvage chemotherapy. The first cycle had a fixed dose of ifosfamide 6 g/m2 and mitoxantrone 12 mg/m2, with arabinosyl cytosine (Ara-C) 2 g/m2, and methylprednisolone 2.0 g. Each cycle of the second and third had cisplatin 90 mg/m2, Ara-C 6 g/m2, methylprednisolone 2...
April 2002: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/11459208/successful-rescue-with-leucovorin-and-thymidine-in-a-patient-with-high-dose-methotrexate-induced-acute-renal-failure
#14
H J van den Bongard, R A Mathĵt, W Boogerd, J H Schornagel, M Soesan, J H Schellens, J H Beijnen
A 54-year-old patient with primary cerebral lymphoma was treated with two 4-weekly cycles of high-dose intravenous cytarabine (12 g/m2) and methotrexate (3 g/m2). The administration of the first course proceeded without notable complications. Before the administration of methotrexate in the second cycle blood cell counts and chemistry showed no abnormalities except for slightly increased alkaline phosphatase and gamma-glutamyl-transpeptidase levels which was attributed to diphantoin comedication. The patient developed symptoms of acute renal failure 7 h after methotrexate infusion which resulted in a very high serum methotrexate level (39...
June 2001: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/11313688/thrombotic-microangiopathy-a-new-dose-limiting-toxicity-of-high-dose-sequential-chemotherapy
#15
J M Vantelon, J N Munck, J H Bourhis, J L Pico, C Fadel, A Ulusakarya, P Carde, P Fenaux, V Ribrag
Ten patients with refractory (n = 8) or early relapsing (n = 2) aggressive non-Hodgkin's lymphoma were enrolled in a pilot study evaluating a high-dose sequential chemotherapy regimen with peripheral blood stem cell (PBSC) support. Five treatment phases were scheduled: phase I (cyclophosphamide + etoposide followed by lenograstim (G-CSF), and a PBSC harvest); phase II (cisplatinum + cytarabine + etoposide followed by lenograstim); phases III and IV (cyclophosphamide + cytarabine + etoposide followed by autologous PBSC infusion and lenograstim); and phase V (carmustine + cytarabine + etoposide + melphalan followed by autologous PBSC infusion and lenograstim)...
March 2001: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/11244328/combined-treatment-with-high-dose-methotrexate-vincristine-and-procarbazine-without-intrathecal-chemotherapy-followed-by-consolidation-radiotherapy-for-primary-central-nervous-system-lymphoma-in-immunocompetent-patients
#16
A J Ferreri, M Reni, S Dell'Oro, F Ciceri, M Bernardi, L Camba, M Ponzoni, M R Terreni, M Tomirotti, M Spina, E Villa
OBJECTIVES: To assess the feasibility and the activity, as well as the efficacy to treat meninges, of chemotherapy (CHT) containing high-dose methotrexate (HD-MTX) followed by radiation therapy (RT), without intrathecal CHT, in patients with primary central nervous system lymphoma. METHODS: Eligibility criteria were histologically proven diagnosis, disease limited to the CNS, age < or = 70, ECOG performance status < or = 3, HIV-negative and no prior treatment...
2001: Oncology
https://www.readbyqxmd.com/read/10853749/oncologist-s-nephropathy
#17
N Nath, G H Neild, P N Plowman
A 46-year-old, previously fit man underwent standard primary chemotherapy and then further standard chemotherapy, followed by high-dose chemotherapy (without total body irradiation) and an autologous marrow transplant for relapsed non-Hodgkin's lymphoma. He also received antibiotics, antifungals and antivirals during this time. He developed episodic renal impairment with remissions, but his renal function never returned to baseline. Renal biopsy demonstrated the lesion to be due to thrombotic microangiopathy; he was treated by an angiotension II receptor antagonist, low-dose aspirin and warfarin...
2000: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/9806652/interferon-alpha-associated-focal-segmental-glomerulosclerosis-with-massive-proteinuria-in-patients-with-chronic-myeloid-leukemia-following-high-dose-chemotherapy
#18
REVIEW
M Shah, E H Jenis, B K Mookerjee, J R Schriber, M R Baer, G P Herzig, M Wetzler
BACKGROUND: Acute renal failure, with or without massive proteinuria, is a rare idiosyncratic toxicity of interferon (IFN)-alpha therapy. The authors sought to review their experience with this toxicity as well as the world literature on the subject. METHODS: The authors describe two patients with chronic myeloid leukemia treated with IFN-alpha following high dose chemotherapy who developed renal failure and proteinuria after 3 and 4 weeks of IFN-alpha therapy, respectively...
November 1, 1998: Cancer
https://www.readbyqxmd.com/read/9763554/incidence-clinical-features-and-outcome-of-all-trans-retinoic-acid-syndrome-in-413-cases-of-newly-diagnosed-acute-promyelocytic-leukemia-the-european-apl-group
#19
RANDOMIZED CONTROLLED TRIAL
S De Botton, H Dombret, M Sanz, J S Miguel, D Caillot, R Zittoun, M Gardembas, A Stamatoulas, E Condé, A Guerci, C Gardin, K Geiser, D C Makhoul, O Reman, J de la Serna, F Lefrere, C Chomienne, C Chastang, L Degos, P Fenaux
All trans-retinoic acid (ATRA) syndrome is a life-threatening complication of uncertain pathogenesis that can occur during the treatment of acute promyelocytic leukemia (APL) by ATRA. Since its initial description, however, no large series of ATRA syndrome has been reported in detail. We analyzed cases of ATRA syndrome observed in an ongoing European trial of treatment of newly diagnosed APL. In this trial, patients 65 years of age or less with an initial white blood cell count (WBC) less than 5,000/microL were initially randomized between ATRA followed by chemotherapy (CT) (ATRA-->CT group) or ATRA with CT started on day 3; patients with WBC greater than 5,000/microL received ATRA and CT from day 1; patients aged 66 to 75 received ATRA-->CT...
October 15, 1998: Blood
https://www.readbyqxmd.com/read/9649146/improved-cure-rate-in-children-with-b-cell-acute-lymphoblastic-leukaemia-b-all-and-stage-iv-b-cell-non-hodgkin-s-lymphoma-b-nhl-results-of-the-ukccsg-9003-protocol
#20
A Atra, M Gerrard, R Hobson, J D Imeson, S Ashley, C R Pinkerton
From June 1990 to February 1996, 35 patients with B-cell acute lymphoblastic leukaemia (B-ALL) 13 of whom had CNS disease and 28 patients with stage IV B-cell non-Hodgkin's lymphoma (B-NHL) 22 of whom had CNS involvement were treated with a short, intensive multiagent chemotherapy regimen (UKCCSG 9003 protocol) based on the French LMB 86 regimen. Fifty-five were boys. The age range was 11 months to 16.5 years (median 8.4 years). Chemotherapy included cyclophosphamide, vincristine, daunorubicin, high-dose methotrexate (COPADM) and etoposide/high-dose cytarabine (CYVE) with frequent intrathecal (i...
June 1998: British Journal of Cancer
keyword
keyword
103077
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"